PEAR THERAPEUTICS, INC.

Analyst Reco. Pear Therapeutics, Inc.

Equities

PEARQ

US7047231052

Market Closed - OTC Markets Other stock markets 07:33:36 22/03/2024 pm IST			5-day change	1st Jan Change
0.000001 ^USD	-99.00%		-.--%	-.--%

22/03	Disclosure Statement and Plan Approved on Interim Basis for Pear Therapeutics, Inc.	CI
04/03	Combined Liquidation Plan and Disclosure Statement Filed by Pear Therapeutics, Inc.	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Credit Suisse Downgrades Pear Therapeutics to Neutral From Outperform, Adjusts Price Target to $1 From $7	20/23/20	MT
TD Cowen Downgrades Pear Therapeutics to Market Perform From Outperform	20/23/20	MT
Chardan Downgrades Pear Therapeutics to Neutral From Buy, Citing Cash Constraints, Withdraws Price Target	20/23/20	MT
Citigroup Adjusts Price Target on Pear Therapeutics to $5 From $7, Maintains Buy Rating	16/22/16	MT
Credit Suisse Lowers Pear Therapeutics' PT to $7 From $9, Updates Model After Q3 Actuals, Management Guidance; Keeps Outperform Rating	15/22/15	MT
Chardan Trims Price Target on Pear Therapeutics to $8 From $9 on Headcount Reduction, Reiterates Buy Rating	15/22/15	MT
Pear Therapeutics Announces Publication of Real-World Data Showing High Rates of Engagement, Retention and Abstinence with reSET®	24/22/24	CI
BTIG Adjusts Price Target for Pear Therapeutics to $5 From $11, Maintains Buy Rating	12/22/12	MT
Chardan Research Lowers Pear Therapeutics' Price Target to $9 From $13, Maintains Buy Rating	12/22/12	MT
Credit Suisse Lowers Pear Therapeutics' Price Target to $9 from $11, Adjusts Guidance While Awaiting Reorganization Impact; Keeps Outperform Rating	26/22/26	MT
BTIG Adjusts Pear Therapeutics' Price Target to $11 from $12, Keeps Buy Rating	24/22/24	MT
Chardan Research Adjusts Price Target for Pear Therapeutics to $13 From $16, Maintains Buy Rating	17/22/17	MT
Citigroup Adjusts Price Target on Pear Therapeutics to $11 From $10, Reiterates Buy Rating	17/22/17	MT
Citigroup Adjusts Pear Therapeutics' Price Target to $12 From $13, Reiterates Buy Rating	29/22/29	MT
BofA Securities Starts Pear Therapeutics at Neutral With $5 Price Target	26/22/26	MT
BTIG Initiates Pear Therapeutics at Buy Rating With $12 Price Target	03/22/03	MT
Citigroup Starts Pear Therapeutics at Buy With $13 Price Target	29/21/29	MT
Chardan Initiates Coverage on Pear Therapeutics With Buy Rating, $16 Price Target	22/21/22	MT
Cowen Starts Pear Therapeutics at Outperform	16/21/16	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

As early as today, start finding the best investment opportunities!

Optimize my profits

fermer